Develop small-molecule single-agent therapies for NASH and obesity. Develop combination therapies for NASH and obesity. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
There is $1.0B in the vault; even if every debt were paid off, $1.0B would remain.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
A loss of $96.2M against $0 in annual sales.
Over the last 12 months, executives reported 75 sells against just 20 buys. Not an alarm bell by itself, but a number worth watching.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.